Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine

Linda B. Adams, Indu Sinha, Scott G. Franzblau, James L. Krahenbuhl, Reeta T. Mehta

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman. Groups of mice were treated with either free clofazimine (F-CLF), L-CLF, or empty liposomes twice a week for five treatments beginning on day 1 (acute), day 21 (established), or day 90 (chronic) postinfection. One day after the last treatment, the numbers of CFU of M. tuberculosis in the spleen, liver, and lungs were determined. F-CLF at the maximum tolerated dose of 5 mg/kg of body weight was ineffective; however, 10-fold-higher doses of L-CLF demonstrated a dose response with significant CFU reduction in all tissues without any toxic effects. In acutely infected mice, 50 mg of L-CLF/kg reduced CFU 2 to 3 log units in all three organs. In established or chronic infection, treated mice showed no detectable CFU in the spleen or liver and 1- to 2-log-unit reduction in the lungs. A second series of L-CLF treatments cleared M. tuberculosis in all three tissues. L-CLF appears to be bactericidal in the liver and spleen, which remained negative for M. tuberculosis growth for 2 months. Thus, L-CLF could be useful in the treatment of tuberculosis.

Original languageEnglish (US)
Pages (from-to)1638-1643
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume43
Issue number7
StatePublished - Jul 1999

Fingerprint

Clofazimine
Liposomes
Tuberculosis
Mycobacterium tuberculosis
Therapeutics
Spleen
Liver
Lung
Maximum Tolerated Dose
Poisons
Body Weight

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Adams, Linda B. ; Sinha, Indu ; Franzblau, Scott G. ; Krahenbuhl, James L. ; Mehta, Reeta T. / Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. In: Antimicrobial Agents and Chemotherapy. 1999 ; Vol. 43, No. 7. pp. 1638-1643.
@article{77a0c9357d0e41668cf1e9aa512fcd1e,
title = "Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine",
abstract = "The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman. Groups of mice were treated with either free clofazimine (F-CLF), L-CLF, or empty liposomes twice a week for five treatments beginning on day 1 (acute), day 21 (established), or day 90 (chronic) postinfection. One day after the last treatment, the numbers of CFU of M. tuberculosis in the spleen, liver, and lungs were determined. F-CLF at the maximum tolerated dose of 5 mg/kg of body weight was ineffective; however, 10-fold-higher doses of L-CLF demonstrated a dose response with significant CFU reduction in all tissues without any toxic effects. In acutely infected mice, 50 mg of L-CLF/kg reduced CFU 2 to 3 log units in all three organs. In established or chronic infection, treated mice showed no detectable CFU in the spleen or liver and 1- to 2-log-unit reduction in the lungs. A second series of L-CLF treatments cleared M. tuberculosis in all three tissues. L-CLF appears to be bactericidal in the liver and spleen, which remained negative for M. tuberculosis growth for 2 months. Thus, L-CLF could be useful in the treatment of tuberculosis.",
author = "Adams, {Linda B.} and Indu Sinha and Franzblau, {Scott G.} and Krahenbuhl, {James L.} and Mehta, {Reeta T.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "43",
pages = "1638--1643",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. / Adams, Linda B.; Sinha, Indu; Franzblau, Scott G.; Krahenbuhl, James L.; Mehta, Reeta T.

In: Antimicrobial Agents and Chemotherapy, Vol. 43, No. 7, 07.1999, p. 1638-1643.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine

AU - Adams, Linda B.

AU - Sinha, Indu

AU - Franzblau, Scott G.

AU - Krahenbuhl, James L.

AU - Mehta, Reeta T.

PY - 1999/7

Y1 - 1999/7

N2 - The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman. Groups of mice were treated with either free clofazimine (F-CLF), L-CLF, or empty liposomes twice a week for five treatments beginning on day 1 (acute), day 21 (established), or day 90 (chronic) postinfection. One day after the last treatment, the numbers of CFU of M. tuberculosis in the spleen, liver, and lungs were determined. F-CLF at the maximum tolerated dose of 5 mg/kg of body weight was ineffective; however, 10-fold-higher doses of L-CLF demonstrated a dose response with significant CFU reduction in all tissues without any toxic effects. In acutely infected mice, 50 mg of L-CLF/kg reduced CFU 2 to 3 log units in all three organs. In established or chronic infection, treated mice showed no detectable CFU in the spleen or liver and 1- to 2-log-unit reduction in the lungs. A second series of L-CLF treatments cleared M. tuberculosis in all three tissues. L-CLF appears to be bactericidal in the liver and spleen, which remained negative for M. tuberculosis growth for 2 months. Thus, L-CLF could be useful in the treatment of tuberculosis.

AB - The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman. Groups of mice were treated with either free clofazimine (F-CLF), L-CLF, or empty liposomes twice a week for five treatments beginning on day 1 (acute), day 21 (established), or day 90 (chronic) postinfection. One day after the last treatment, the numbers of CFU of M. tuberculosis in the spleen, liver, and lungs were determined. F-CLF at the maximum tolerated dose of 5 mg/kg of body weight was ineffective; however, 10-fold-higher doses of L-CLF demonstrated a dose response with significant CFU reduction in all tissues without any toxic effects. In acutely infected mice, 50 mg of L-CLF/kg reduced CFU 2 to 3 log units in all three organs. In established or chronic infection, treated mice showed no detectable CFU in the spleen or liver and 1- to 2-log-unit reduction in the lungs. A second series of L-CLF treatments cleared M. tuberculosis in all three tissues. L-CLF appears to be bactericidal in the liver and spleen, which remained negative for M. tuberculosis growth for 2 months. Thus, L-CLF could be useful in the treatment of tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0032798081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032798081&partnerID=8YFLogxK

M3 - Article

C2 - 10390215

AN - SCOPUS:0032798081

VL - 43

SP - 1638

EP - 1643

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -